Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

Shares of the parent companies of pharmacy benefit managers fell Tuesday after President-elect Donald Trump and others ...

Pfizer shares rallied after the drugmaker's 2025 guidance met Wall Street expectations, cheering shareholders as the ...

Judge Katharine H Parker, handling Luigi Mangione's pre-trial hearings, is married to a former Pfizer executive and holds ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

Pfizer on Tuesday forecast 2025 profits roughly in line with Wall Street expectations, offering some relief to investors ...

Pfizer on Tuesday forecast 2025 profit roughly in line with estimates, offering some relief to investors after the drugmaker ...

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

Pfizer’s financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a "Buy" ...

The Vyndaqel family of drugs for the treatment of transthyretin amyloid cardiomyopathy is Pfizer’s fourth top-selling product ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...